Share on StockTwits
 

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group in a research report issued on Thursday, Analyst Ratings Network.com reports. They currently have a GBX 3,080 ($50.62) price target on the stock. Jefferies Group’s price target would indicate a potential downside of 19.28% from the company’s current price.

Shares of AstraZeneca (LON:AZN) traded down 1.59% on Thursday, hitting GBX 3815.50. The stock had a trading volume of 5,586,882 shares. AstraZeneca has a 52-week low of GBX 2895.00 and a 52-week high of GBX 3964.50. The stock has a 50-day moving average of GBX 3727.14 and a 200-day moving average of GBX 3387.81. The company’s market cap is £47.808 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Panmure Gordon reiterated a “sell” rating on shares of AstraZeneca in a research note to investors on Wednesday. They now have a GBX 3,500 ($57.52) price target on the stock. Separately, analysts at Nordea Equity Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Friday, January 31st. They now have a GBX 4,469.30 ($73.45) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, January 28th. They now have a GBX 3,700 ($60.81) price target on the stock. Ten investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 3,395.85 ($55.81).

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.